NCT04134312View on ClinicalTrials.gov

A Phase 1 Open Label Trial of Intravenous Administration of MVA-BN-Brachyury Vaccine in Patients With Advanced Cancer

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 8, 2020

Primary Completion Date

January 12, 2021

Study Completion Date

April 6, 2021

Conditions

Solid Metastatic Tumor

Interventions

BIOLOGICAL

MVA-BN-Brachyury

MVA-BN-Brachyury will be administered intravenously every three weeks with three administrations in total at the dose indicated by the enrolled cohort.

Trial Locations (1)

20892

National Cancer Institute, Bethesda